News for Biomark Diagnostics Inc (BMKDF)

BioMark Diagnostics (BMKDF) achieves over 93% accuracy with its lung cancer test. The test differentiates early-stage lung cancer from non-cancerous lung co

BioMark Diagnostics Inc. , an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that the Company intends to amend the terms of 5,062,000...

BioMark Diagnostics Inc. , an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce today that it has closed a financing round to accelerate...

Vancouver, British Columbia - December 4, 2023 (Newsfile Corp.) (Investorideas.com Newswire) BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("...

Biomark Diagnostics Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported sales was CAD 0.153492 million compared to CAD 0.043933 million a...

BioMark Diagnostics Inc. , an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, is pleased to announce that its latest leading-edge research was presented... | June 5, 2023

Cancer Diagnostics Market Size, Trends and Industry Outlook by Type (Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and others),...

BioMark Diagnostics Inc.   an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the... | January 11, 2023

Form 7 Monthly Progress Report November 1 2022 Name of Listed... | January 9, 2023

BioMark Diagnostics Inc. press release (BMKDF): Q2  cash, short-term investments, and long-term investments stood at C$1,007,907 compared to t C$629,552 as of September 30,...